European Menopause and Andropause Society (EMAS)
E-Learning
Presentations
Webcast
E-posters

Presentations 

Disclaimer: The information contained on this page has been submitted by the Author. As such, the responsibility of content remains with the Author and is not an official statement from EMAS.This material is to be used for educational purposes only and is not intended for commercial use.  No information may be copied or cited without prior consent from the Author. The products mentioned are not necessarily endorsed by the Author. For any further information, please contact the EMAS secretariat.

eMAS lectures at IMS June 2011

Treatment of menopausal symptoms in breast cancer survivors S. Rozenberg 

Risk factors and prevalence of women's health cancers in Europe S. Rozenberg 

Menopausal Symptoms as markers of CVD disease susceptibility M. Gambacciani

Management of Osteoporosis in Europe I. Lambrinoudaki

Subclinical CVD I. Lambrinoudaki

eMAS lectures at vienna 2010

Obesity and cardiovascular disease epidemics: a time for reflection. M.Rees

Alternative treatment of hot flashes from an evidence based perspective. M. Moen

COMING SOON
Breast cancer: evolution of incident rates in Europe in relation to HRT? S. Rozenberg

EMAS lecture at EBCOG, Antwerp, May 2010

HRT & CHD is there evidence for a window of opportunity? Dr.Marco Gambacciono

Should osteoporosis prevention start at the menopause or should we only target women at high risk? Prof.Marc Brincat, Dr.J.Calleja-Agius

Making sense of HT after menopause: is there a place for HT in view of the stroke risk? Prof.Serge Rozenberg

Is postmenopause hormone therapy acceptable in view of breast cancer risk? Dr.Irene Lambrinoudaki

8th European Congress on Menopause, 16-20 May 2009, London, UK

Plenary Lectures

Monday, 18 May, 2009


An aging world- Challenges ahead B. Lunenfeld, Israel

Debates

Monday, 18 May, 2009

DEBATE: PROGESTIN OR PROGESTERONE – THERE IS NO REAL DIFFERENCE Introduction  A. Gompel, France
 
Progestin or progesterone - There is no real difference M. Dören, Germany
 
Progesterone and progestins: There are real differences J. Desreux, A. Béliard, E. Lifrange, J.-M. Foidart, Belgium

Tuesday, 19 May, 2009


DEBATE: LONG-TERM PREVENTION OF OSTEOPOROSIS STARTING AT THE MENOPAUSE IS PREFERABLE TO LATER TARGETING OF WOMEN AT HIGH FRACTURE RISK
  Long -term prevention of osteoporosis starting at the menopause
is preferable to later targeting of women at a high fracture risk
C. Christiansen, Denmark

Parallel Sessions

Sunday, 17 May, 2009


PARALLEL SESSION: BREAST MANAGEMENT
Managing oestrogen deficiency after breast cancer S. Rozenberg, C. Antoine, B. Carly, F. Liebens, Belgium

PARALLEL SESSION: OBESITY AND HEALTH IN POST-MENOPAUSAL WOMEN Obesity-a silent killer? R. Kaaks, Germany
 
Impact of obesity on symptoms of the menopause M.A. Lumsden, UK
 
Management of obesity in menopause  G. Mastorakos, G. Paltoglou, Greece

PARALLEL SESSION: THE AGEING MALE - LATE ONSET HYPOGONADISM (LOH) Safety W. Weidner, Germany
 
ISSAM recommendations for the management of late onset hypogonadism B. Lunenfeld, Israel

PARALLEL SESSION: HRT & BREAST CANCER RISK Decrease in breast cancer incidence and HRT A. Gompel, G. Plu-Bureau, France
 
What is the impact of HRT on screening B. von Schoultz, Sweden

PARALLEL SESSION: NEW DEVELOPMENTS FOR TOMORROW Contribution of molecular biology tools M. Ivan, USA

PARALLEL SESSION: URO-GENITAL AGEING Managing URO-genital atrophy G. Samsioe, Sweden
 
Maintaining standards in surgery for female urinary incontinence P. Riss, Austria

Monday, 18 May, 2009

PARALLEL SESSION: PERIMENOPAUSE Contraception after 45 A. Szarewski, UK
 
Aetiology of premature ovarian failure S. Vujovic, Serbia
 
Managing premature ovarian failure N. Panay, UK

Tuesday, 19 May, 2009


PARALLEL SESSION: SEXUAL FUNCTION
Sexuality in older couples M. Lachowsky, France

PARALLEL SESSION: PROFESSIONAL DEVELOPMENT IN MENOPAUSE PRACTICE - EUROPE UK special interest training in menopause S. Gray, UK
 
Training for menopause practice in Scandinavia M.H. Moen, Norway

PARALLEL SESSION: CARDIOVASCULAR DISEASE Is there really a window of opportunity? J.C. Stevenson, UK
 
The risk of stroke in postmenopausal women receiving hormonal therapy R.A. Lobo, USA

PARALLEL SESSION: SEXUAL HEALTH Improving immunity in the climateric years F. Al-Azzawi, UK
 
PARALLEL SESSION: THE MENOPAUSAL UTERUS AND OVARY Understanding uterine bleeding M. Rees, UK
 
Benign gynaecology after menopause H. Retto, Portugal

Wednesday, 20 May, 2009


PARALLEL SESSION: OSTEOPOROSIS AND FRACTURE
Advances in non-hormonal drug therapy for fracture prevention
E. Dennison, UK
 
Vertebral body quality, effect of HRT and fracture prevention in osteoporosis M. Brincat, J. Calleja-Agius, Y. Muscat-Baron, Malta

PARALLEL SESSION: INDIVIDUALISING THERAPY FOR CLIMACTERIC SYMPTOMS Vasomotor symptoms
D. Sturdee, UK

Joint aches & pains: individualising therapy for climacteric symptoms M. Gambacciani, Italy